ClinicalTrials.gg
CompletedNCT01133626Updated Jul 4, 2012Results posted

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

A Phase 3 interventional study of Placebo Nasal Aerosol and Prednisone capsules in Perennial Allergic Rhinitis, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 3 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-07-04.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
12 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.

Enrollment
36th of 57
107 · median 301
Started
2010
with 4 others
Phase 3
33 of 60
none open now
Registered
43rd of 60
by date
Lead sponsor
4 of 60
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 36th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 43rd registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 12 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 60 studies in Rhinitis, Allergic, Perennial with a site in United States as a file.
02

Study summary

The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.

03

Conditions studied

  • Perennial Allergic Rhinitis
04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 12-45 years of age
  • Documented history of perennial allergic rhinitis
  • General good health
  • Other criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)
  • Participation in any drug study 30 days preceding Screening Visit 1
  • History of respiratory infection/disorder with 14 days preceding Screening Visit 1
  • Use of any prohibited concomitant medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
107 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.

    Drug: Placebo Nasal Aerosol · Drug: Placebo Prednisone Capsules

  • Experimental
    BDP HFA 320 µg/day

    Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.

    Drug: Placebo Prednisone Capsules · Drug: Beclomethasone dipropionate

  • Active comparator
    Prednisone

    Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.

    Drug: Placebo Nasal Aerosol · Drug: Prednisone capsules

Interventions

  • DrugPlacebo Nasal Aerosol

    Placebo nasal aerosol administered daily for 42 days of treatment

  • Prednisone 10 mg capsule taken each day on the last 7 days of treatment

  • DrugPlacebo Prednisone Capsules

    Placebo prednisone capsule taken each day on the last 7 days of treatment

  • Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.

    Also known as: QNASL(TM)

06

What researchers measure

Primary outcomes

  1. The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment

    Geometric mean serum cortisol weighted mean values were calculated at baseline and after 6 weeks (42 days) of treatment. The geometric mean ratio of week 6 / baseline is reported. The primary outcome compares the BDP HFA and Placebo treatment arms. The comparison of active control (Placebo/Prednisone) and Placebo treatment arms is an "other pre-specified" outcome.

    Time frame: Day 0 (Baseline), Day 42

07

Results

Posted Jul 4, 2012

Participant flow

A total of 139 patients were screened and 128 patients were enrolled in the study and participated in the Run-in Period. Of the 128 enrolled patients, 107 were randomized to study treatment.

Participant flow — Overall Study
MilestoneBDP HFA 320 µg/DayPlaceboPlacebo/Prednisone
Started504611
Safety population504611
Per protocol population48419
Completed49419
Not completed152
Withdrew: Adverse event010
Withdrew: Withdrawal by subject122
Withdrew: Other020

Outcome measures

PrimaryThe 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment

Geometric mean serum cortisol weighted mean values were calculated at baseline and after 6 weeks (42 days) of treatment. The geometric mean ratio of week 6 / baseline is reported. The primary outcome compares the BDP HFA and Placebo treatment arms. The comparison of active control (Placebo/Prednisone) and Placebo treatment arms is an "other pre-specified" outcome.

Time frame:
Day 0 (Baseline), Day 42
Reported as:
Geometric mean · ratio
The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment
ratioBDP HFA 320 µg/DayPlaceboPlacebo/Prednisone
The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment0.90 ± 1.040.95 ± 1.030.31 ± 1.14
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · Geometric mean ratio: 0.96 · 95% CI 0.87 to 1.06

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP HFA 320 µg/Day—0/50 (0%)3/50 (6%)
Placebo—0/46 (0%)3/46 (6.5%)
Placebo/Prednisone—0/11 (0%)5/11 (45.5%)
Most frequent other events
Most frequent other events
EventBDP HFA 320 µg/DayPlaceboPlacebo/Prednisone
GastroenteritisInfections and infestations0/500/461/11
Blood oestrogen increasedInvestigations0/500/461/11
DysphoniaRespiratory, thoracic and mediastinal disorders0/500/461/11
EpistaxisRespiratory, thoracic and mediastinal disorders2/501/461/11
Nasal discomfortRespiratory, thoracic and mediastinal disorders1/502/461/11

Baseline characteristics

Age Continuous
Age Continuous(years)BDP HFA 320 µg/DayPlaceboPlacebo/PrednisoneTotal
Mean28.3 ± 10.026.6 ± 10.626.2 ± 11.927.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)BDP HFA 320 µg/DayPlaceboPlacebo/PrednisoneTotal
Female2522754
Male2319244
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 320 µg/DayPlaceboPlacebo/PrednisoneTotal
Hispanic or Latino1817237
Not Hispanic or Latino3024761
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 320 µg/DayPlaceboPlacebo/PrednisoneTotal
American Indian or Alaska Native0011
Asian1001
Black or African American72110
White4238787
Unknown or Not Reported0101
Body Mass Index
Body Mass Index(kg/m^2)BDP HFA 320 µg/DayPlaceboPlacebo/PrednisoneTotal
Mean27.9 ± 7.927.0 ± 6.228.4 ± 7.927.6 ± 7.2
08

Study locations

3 sites
  • Teva Clinical Study Site
    North Dartmouth, Massachusetts 02747, United States
  • Teva Clinical Study Site
    New Braunfels, Texas 78130, United States
  • Teva Clinical Study Site
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Hampel FC, Ratner PH, Miller SD, Melchior A, Dunbar SA, Tantry SK, Dorinsky PM. Once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol (320 mcg/d) is not associated with hypothalamic-pituitary-adrenal axis suppression in adolescent subjects with perennial allergic rhinitis. J Allergy Clin Immunol 2012; 129:AB188
  • Ratner PH, Miller SD, Hampel FC, A, Dunbar SA, Tantry SK, Dorinsky PM (2011). BDP HFA Nasal Aerosol 320 μg Once Daily g Once Daily Is Not Associated with HPA-Axis Suppression in Subjects With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol. 107(11):A118.
  • Ratner PH, Miller SD, Hampel FC Jr, Melchior A, Dunbar SA, Tantry SK. Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function. Ann Allergy Asthma Immunol. 2012 Nov;109(5):336-41. doi: 10.1016/j.anai.2012.08.005. PubMed 23062389 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 10 months after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
May 31, 2010
Start
Jun 2010
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results delay requested
Aug 25, 2011
Results first posted
Jul 4, 2012
Last update
Jul 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01133626
Responsible party
Sponsor
First posted
May 31, 2010
Start date
Jun 2010
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Jul 4, 2012
Last update
Jul 4, 2012

Study contacts

Sudeesh K. Tantry, Ph.D.
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion